终于来了!《药物真实世界研究设计与方案框架指导原则(征求意见稿)》

2022-07-08 CDE CDE

为了指导申办者科学合理的设计真实世界研究,明确真实世界研究方案撰写的技术要求,我中心组织起草了《药物真实世界研究设计与方案框架指导原则(征求意见稿)》,现公开征求意见。欢迎各界提出宝贵意见和建议,并请

为了指导申办者科学合理的设计真实世界研究,明确真实世界研究方案撰写的技术要求,我中心组织起草了《药物真实世界研究设计与方案框架指导原则(征求意见稿)》,现公开征求意见。欢迎各界提出宝贵意见和建议,并请及时反馈给我们。征求意见时限为自发布之日起2个月。

具体下载见:药物真实世界研究设计与方案框架指导原则(征求意见稿)

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1949978, encodeId=fe5519499e86a, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 03 01:55:16 CST 2023, time=2023-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009785, encodeId=1a7e2009e8553, content=<a href='/topic/show?id=8d6750352ef' target=_blank style='color:#2F92EE;'>#征求意见稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50352, encryptionId=8d6750352ef, topicName=征求意见稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Aug 08 02:55:16 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295405, encodeId=d886129540592, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jul 09 22:55:16 CST 2022, time=2022-07-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1949978, encodeId=fe5519499e86a, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 03 01:55:16 CST 2023, time=2023-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009785, encodeId=1a7e2009e8553, content=<a href='/topic/show?id=8d6750352ef' target=_blank style='color:#2F92EE;'>#征求意见稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50352, encryptionId=8d6750352ef, topicName=征求意见稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Aug 08 02:55:16 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295405, encodeId=d886129540592, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jul 09 22:55:16 CST 2022, time=2022-07-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1949978, encodeId=fe5519499e86a, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Mar 03 01:55:16 CST 2023, time=2023-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2009785, encodeId=1a7e2009e8553, content=<a href='/topic/show?id=8d6750352ef' target=_blank style='color:#2F92EE;'>#征求意见稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50352, encryptionId=8d6750352ef, topicName=征求意见稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Mon Aug 08 02:55:16 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295405, encodeId=d886129540592, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Jul 09 22:55:16 CST 2022, time=2022-07-09, status=1, ipAttribution=)]

相关资讯

队列研究和真实世界研究之间有什么区别?

队列研究和真实世界研究之间有什么区别-第十四个问题

真实世界研究成功的关键是什么?姚晨教授:这三点做到很容易!

在药物及医疗器械的研发中,随机对照试验(Randomized Controlled Trials,RCTs)被认为是评价有效性和安全性的金标准。RCT严格控制入组条件并进行随机分组,能够最大限度地减少

ARD:IL-12/23通路抑制剂优特克单抗或TNFi 治疗银屑病关节炎患者的持久性和有效性相当

在现实世界的PsABio研究中,经过1年的治疗,倾向评分调整后的比较显示出优特克单抗和肿瘤坏死因子抑制剂(TNFi)对银屑病关节炎治疗具有相当的整体持久性、有效性和安全性。

第十届中国罕见病高峰论坛在杭举行,真实世界数据研究在罕见病中应用渐入佳境

2021年9月10日-12日,第十届中国罕见病高峰论坛在杭州隆重召开。会议以“罕路同行 十载与共”为主题,由蔻德罕见病中心(CORD)、浙江大学医学院、浙江大学医学院附属第二医

第十届中国罕见病高峰论坛在杭举行,真实世界数据研究在罕见病应用渐入佳境

2021年9月10日-12日,第十届中国罕见病高峰论坛在杭州隆重召开。会议以“罕路同行 十载与共”为主题,由蔻德罕见病中心(CORD)、浙江大学医学院、浙江大学医学院附属第二医